{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:48:20Z","timestamp":1777268900781,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatic sinusoidal obstruction syndrome (SOS)\/veno-occlusive disease (VOD) is a complication after allogenic hematopoietic stem-cell transplantation (allo-HSCT) with high mortality. The purpose of this study was to assess the incidence and outcome of SOS in patients after allo-HSCT with the impact of ursodeoxycholic acid (UDCA) and low-dose heparin as SOS prophylaxis. Out of 1016 patients, 23 developed SOS, with a cumulative incidence of 2.3% (95% CI 1.3\u20133.3) 6 months after HSCT. Approximately one quarter of these patients (26.1%) had late-onset SOS. A high proportion were very severe SOS cases (74%), and 83% of the patients were treated with defibrotide (DF). In multivariate analysis, advanced disease (<jats:italic>p<\/jats:italic>\u2009=\u20090.003), previous HSCT (<jats:italic>p<\/jats:italic>\u2009=\u20090.025) and graft versus host disease (GvHD) prophylaxis by post-transplant cyclophosphamide (PTCy) (<jats:italic>p<\/jats:italic>\u2009=\u20090.055) were associated with the development of SOS. The 1-year overall survival (OS) was significantly lower in the SOS group compared to patients without SOS (13% versus 70%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0001). In conclusion, we found a low incidence of SOS in patients receiving low-dose heparin and UDCA prophylactically, but among SOS patients, a high mortality. Low-dose heparin and UDCA might be a prophylactic approach for SOS.<\/jats:p>","DOI":"10.1038\/s41409-021-01546-w","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:03:01Z","timestamp":1641254581000},"page":"391-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Low Incidence of hepatic sinusoidal obstruction syndrome\/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin"],"prefix":"10.1038","volume":"57","author":[{"given":"Lina","family":"Stutz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-1956","authenticated-orcid":false,"given":"J\u00f6rg P.","family":"Halter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Heim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob R.","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0427-7747","authenticated-orcid":false,"given":"Michael","family":"Medinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"1546_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl. 2016;22:400\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","volume":"11","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Barbato F, Ravaioli F, Sessa M, Defrancesco I, Arpinati M, et al. Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489.","journal-title":"Front Immunol"},{"key":"1546_CR3","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2011.65","volume":"46","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transpl. 2011;46:1495\u2013502.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2016;51:906\u201312.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","volume":"55","author":"M Mohty","year":"2020","unstructured":"Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transpl. 2020;55:485\u201395.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbmt.2019.10.024","volume":"26","author":"C Lewis","year":"2020","unstructured":"Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, et al. Incidence, predictors, and outcomes of veno-occlusive disease\/sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2020;26:529\u201339.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR7","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998;92:3599\u2013604.","journal-title":"Blood"},{"key":"1546_CR8","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.bbmt.2018.06.013","volume":"24","author":"C Strouse","year":"2018","unstructured":"Strouse C, Zhang Y, Zhang MJ, DiGilio A, Pasquini M, Horowitz MM, et al. Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transpl. 2018;24:2072\u201380.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR9","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/s41409-021-01215-y","volume":"56","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Incidence and risk factors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. Bone Marrow Transplant 2021;56:1603\u201313.","journal-title":"Bone Marrow Transplant"},{"key":"1546_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157\u201368.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR11","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.bbmt.2016.04.011","volume":"22","author":"C Strouse","year":"2016","unstructured":"Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, et al. Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2016;22:1306\u201312.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR12","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 2016;127:1656\u201365.","journal-title":"Blood"},{"key":"1546_CR13","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41409-019-0474-8","volume":"54","author":"P Richardson","year":"2019","unstructured":"Richardson P, Aggarwal S, Topaloglu O, Villa KF, Corbacioglu S. Systematic review of defibrotide studies in the treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS). Bone Marrow Transpl. 2019;54:1951\u201362.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-136685","volume":"136","author":"M Mohty","year":"2020","unstructured":"Mohty M, Yakoub-Agha I, Labopin M, Blaise D, Lebon D, Gandemer V, et al. Final primary results from the defifrance registry study: effectiveness and safety of defibrotide in the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after hematopoietic cell transplantation. Blood 2020;136:35\u20136. Supplement 1","journal-title":"Blood"},{"key":"1546_CR15","doi-asserted-by":"crossref","unstructured":"Ruutu T CE. Hepatic Complications. In: Carreras EDC, Mohty M, Kr\u00f6ger N, editor. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. 7 ed: Springer, Cham; 2019. p. 373\u20139.","DOI":"10.1007\/978-3-030-02278-5_49"},{"key":"1546_CR16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, et al. BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013;163:444\u201357.","journal-title":"Br J Haematol"},{"key":"1546_CR17","unstructured":"Defitelio Summary of Product Characteristics [28.09.2021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/defitelio-epar-product-information_en.pdf."},{"key":"1546_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012;379:1301\u20139.","journal-title":"Lancet"},{"key":"1546_CR19","unstructured":"Study comparing efficacy and safety of defibrotide vs best supportive care in the prevention of hepatic veno-occlusive disease in adult and pediatric patients [14.06.2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02851407."},{"key":"1546_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/13696998.2021.1929259","volume":"24","author":"A Gratwohl","year":"2021","unstructured":"Gratwohl A. Cost-effectiveness of defibrotide for treatment of severe veno-occlusive disease: it is time for evidence based economic evaluations. J Med Econ 2021;24:727\u20139.","journal-title":"J Med Econ"},{"key":"1546_CR21","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/13696998.2021.1916749","volume":"24","author":"D Carcedo Rodriguez","year":"2021","unstructured":"Carcedo Rodriguez D, Artola Urain T, Chinea Rodriguez A, Garcia Torres E, Gonzalez Vicent M, Gutierrez Garcia G, et al. Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease\/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain. J Med Econ 2021;24:628\u201336.","journal-title":"J Med Econ"},{"key":"1546_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bmt.1705297","volume":"37","author":"H Imran","year":"2006","unstructured":"Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transpl. 2006;37:677\u201386.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR23","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834","volume":"79","author":"M Attal","year":"1992","unstructured":"Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992;79:2834\u201340.","journal-title":"Blood"},{"key":"1546_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","volume":"13","author":"J Tay","year":"2007","unstructured":"Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2007;13:206\u201317.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbmt.2013.10.014","volume":"20","author":"T Ruutu","year":"2014","unstructured":"Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transpl. 2014;20:135\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bmt.1703342","volume":"29","author":"SH Park","year":"2002","unstructured":"Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2002;29:137\u201343.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"1546_CR28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00277-018-3577-1","volume":"98","author":"M Bianchi","year":"2019","unstructured":"Bianchi M, Heim D, Lengerke C, Halter J, Gerull S, Kleber M, et al. Cyclosporine levels >195 mug\/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2019;98:971\u20137.","journal-title":"Ann Hematol"},{"key":"1546_CR29","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR30","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/bmt.2015.148","volume":"50","author":"L Binkert","year":"2015","unstructured":"Binkert L, Medinger M, Halter JP, Heim D, Gerull S, Holbro A, et al. Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation. Bone Marrow Transpl. 2015;50:1331\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR31","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1546_CR32","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/bmt.2012.45","volume":"47","author":"T Ruutu","year":"2012","unstructured":"Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2012;47:1459\u201364.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41409-018-0293-3","volume":"54","author":"S Kraft","year":"2019","unstructured":"Kraft S, Bollinger N, Bodenmann B, Heim D, Bucher C, Lengerke C, et al. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. Bone Marrow Transpl. 2019;54:540\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR34","first-page":"5","volume":"55","author":"P Jacobs","year":"1979","unstructured":"Jacobs P, Miller JL, Uys CJ, Dietrich BE. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia. S Afr Med J 1979;55:5\u201310.","journal-title":"S Afr Med J"},{"key":"1546_CR35","doi-asserted-by":"crossref","unstructured":"Cheuk DK, Chiang AK, Ha SY, Chan GC Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015:CD009311.","DOI":"10.1002\/14651858.CD009311.pub2"},{"key":"1546_CR36","doi-asserted-by":"publisher","first-page":"102827","DOI":"10.1016\/j.transci.2020.102827","volume":"59","author":"N Soyer","year":"2020","unstructured":"Soyer N, Gunduz M, Tekgunduz E, Deveci B, Ozdogu H, Sahin HH, et al. Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of Turkish hematology research and education group (ThREG). Transfus Apher Sci 2020;59:102827.","journal-title":"Transfus Apher Sci"},{"key":"1546_CR37","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/ajt.16345","volume":"21","author":"V Mehra","year":"2021","unstructured":"Mehra V, Tetlow S, Choy A, de Lavallade H, Kulasekararaj A, Krishnamurthy P, et al. Early and late-onset veno-occlusive disease\/sinusoidal syndrome post allogeneic stem cell transplantation - a real-world UK experience. Am J Transplant 2021;21:864\u20139.","journal-title":"Am J Transplant"},{"key":"1546_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00277-019-03604-2","volume":"98","author":"CC Lee","year":"2019","unstructured":"Lee CC, Chang HH, Lu MY, Yang YL, Chou SW, Lin DT, et al. The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan. Ann Hematol 2019;98:745\u201352.","journal-title":"Ann Hematol"},{"key":"1546_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbmt.2018.07.039","volume":"25","author":"LE Roeker","year":"2019","unstructured":"Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, et al. Early clinical predictors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after myeloablative stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:137\u201344.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR40","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","volume":"2","author":"A Gratwohl","year":"2015","unstructured":"Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e91\u2013100.","journal-title":"Lancet Haematol"},{"key":"1546_CR41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15267","volume":"181","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Br J Haematol 2018;181:816\u201327.","journal-title":"Br J Haematol"},{"key":"1546_CR42","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.bbmt.2019.12.763","volume":"26","author":"VT Ho","year":"2020","unstructured":"Ho VT, Martin AS, Perez WS, Steinert P, Zhang MJ, Chirnomas D, et al. Prior gemtuzumab ozogamicin exposure in adults with acute myeloid leukemia does not increase hepatic veno-occlusive disease risk after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transpl. 2020;26:884\u201392.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transpl. 2016;51:403\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"1546_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bbmt.2019.12.655","volume":"26","author":"S Corbacioglu","year":"2020","unstructured":"Corbacioglu S. A systematic review of studies of defibrotide prophylaxis for veno-occlusive disease\/sinusoidal obstruction syndrome. Biol Blood Marrow Transpl. 2020;26:133.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1546_CR45","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.bbmt.2018.02.015","volume":"24","author":"A Picod","year":"2018","unstructured":"Picod A, Bonnin A, Battipaglia G, Giannotti F, Ruggeri A, Brissot E, et al. Defibrotide for sinusoidal obstruction syndrome\/veno-occlusive disease prophylaxis in high-risk adult patients: a single-center experience study. Biol Blood Marrow Transpl. 2018;24:1471\u20135.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01546-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T22:05:48Z","timestamp":1676066748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01546-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01546-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the local ethics committee (EKNZ study number: 2020-02784).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}